321 related articles for article (PubMed ID: 20570895)
1. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy.
Agarwal A; Tressel SL; Kaimal R; Balla M; Lam FH; Covic L; Kuliopulos A
Cancer Res; 2010 Jul; 70(14):5880-90. PubMed ID: 20570895
[TBL] [Abstract][Full Text] [Related]
2. GRO-α and IL-8 enhance ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade.
Yung MM; Tang HW; Cai PC; Leung TH; Ngu SF; Chan KK; Xu D; Yang H; Ngan HY; Chan DW
Theranostics; 2018; 8(5):1270-1285. PubMed ID: 29507619
[TBL] [Abstract][Full Text] [Related]
3. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
[TBL] [Abstract][Full Text] [Related]
4. Growth-regulated oncogene is pivotal in thrombin-induced angiogenesis.
Caunt M; Hu L; Tang T; Brooks PC; Ibrahim S; Karpatkin S
Cancer Res; 2006 Apr; 66(8):4125-32. PubMed ID: 16618733
[TBL] [Abstract][Full Text] [Related]
5. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Devapatla B; Sharma A; Woo S
PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
[TBL] [Abstract][Full Text] [Related]
6. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis.
Yang G; Rosen DG; Liu G; Yang F; Guo X; Xiao X; Xue F; Mercado-Uribe I; Huang J; Lin SH; Mills GB; Liu J
Clin Cancer Res; 2010 Aug; 16(15):3875-86. PubMed ID: 20505188
[TBL] [Abstract][Full Text] [Related]
7. Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer.
Kaimal R; Aljumaily R; Tressel SL; Pradhan RV; Covic L; Kuliopulos A; Zarwan C; Kim YB; Sharifi S; Agarwal A
Cancer Res; 2013 Apr; 73(8):2457-2467. PubMed ID: 23423981
[TBL] [Abstract][Full Text] [Related]
8. Human endothelial cells promote arsenic-transformed lung epithelial cells to induce tumor growth and angiogenesis through interleukin-8 induction.
Zhao L; Wang YF; Liu J; Jiang BH; Liu LZ
Aging (Albany NY); 2022 Mar; 14(5):2113-2130. PubMed ID: 35241635
[TBL] [Abstract][Full Text] [Related]
9. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment.
Zhang T; Tseng C; Zhang Y; Sirin O; Corn PG; Li-Ning-Tapia EM; Troncoso P; Davis J; Pettaway C; Ward J; Frazier ML; Logothetis C; Kolonin MG
Nat Commun; 2016 May; 7():11674. PubMed ID: 27241286
[TBL] [Abstract][Full Text] [Related]
10. PAR1-stimulated platelet releasate promotes angiogenic activities of endothelial progenitor cells more potently than PAR4-stimulated platelet releasate.
Huang Z; Miao X; Luan Y; Zhu L; Kong F; Lu Q; Pernow J; Nilsson G; Li N
J Thromb Haemost; 2015 Mar; 13(3):465-76. PubMed ID: 25495701
[TBL] [Abstract][Full Text] [Related]
11. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression.
Gabellini C; Trisciuoglio D; Desideri M; Candiloro A; Ragazzoni Y; Orlandi A; Zupi G; Del Bufalo D
Eur J Cancer; 2009 Sep; 45(14):2618-27. PubMed ID: 19683430
[TBL] [Abstract][Full Text] [Related]
12. NF-κB contributes to MMP1 expression in breast cancer spheroids causing paracrine PAR1 activation and disintegrations in the lymph endothelial barrier in vitro.
Nguyen CH; Senfter D; Basilio J; Holzner S; Stadler S; Krieger S; Huttary N; Milovanovic D; Viola K; Simonitsch-Klupp I; Jäger W; de Martin R; Krupitza G
Oncotarget; 2015 Nov; 6(36):39262-75. PubMed ID: 26513020
[TBL] [Abstract][Full Text] [Related]
13. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.
Agarwal A; Covic L; Sevigny LM; Kaneider NC; Lazarides K; Azabdaftari G; Sharifi S; Kuliopulos A
Mol Cancer Ther; 2008 Sep; 7(9):2746-57. PubMed ID: 18790755
[TBL] [Abstract][Full Text] [Related]
14. Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo.
Sinha S; Pal K; Elkhanany A; Dutta S; Cao Y; Mondal G; Iyer S; Somasundaram V; Couch FJ; Shridhar V; Bhattacharya R; Mukhopadhyay D; Srinivas P
Int J Cancer; 2013 Mar; 132(5):1201-12. PubMed ID: 22806981
[TBL] [Abstract][Full Text] [Related]
15. Epithelial-stromal communication via CXCL1-CXCR2 interaction stimulates growth of ovarian cancer cells through p38 activation.
Park GY; Pathak HB; Godwin AK; Kwon Y
Cell Oncol (Dordr); 2021 Feb; 44(1):77-92. PubMed ID: 32910411
[TBL] [Abstract][Full Text] [Related]
16. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis.
Yang E; Boire A; Agarwal A; Nguyen N; O'Callaghan K; Tu P; Kuliopulos A; Covic L
Cancer Res; 2009 Aug; 69(15):6223-31. PubMed ID: 19622769
[TBL] [Abstract][Full Text] [Related]
17. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
Khan MN; Wang B; Wei J; Zhang Y; Li Q; Luan X; Cheng JW; Gordon JR; Li F; Liu H
Oncotarget; 2015 Aug; 6(25):21315-27. PubMed ID: 26087179
[TBL] [Abstract][Full Text] [Related]
18. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
19. Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.
Rana R; Huang T; Koukos G; Fletcher EK; Turner SE; Shearer A; Gurbel PA; Rade JJ; Kimmelstiel CD; Bliden KP; Covic L; Kuliopulos A
Arterioscler Thromb Vasc Biol; 2018 Jun; 38(6):1368-1380. PubMed ID: 29622563
[TBL] [Abstract][Full Text] [Related]
20. MMP1/PAR1/SP/NK1R paracrine loop modulates early perineural invasion of pancreatic cancer cells.
Huang C; Li Y; Guo Y; Zhang Z; Lian G; Chen Y; Li J; Su Y; Li J; Yang K; Chen S; Su H; Huang K; Zeng L
Theranostics; 2018; 8(11):3074-3086. PubMed ID: 29896303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
